SGMT Sagimet Biosciences Inc.

NASDAQ
$10.55

Sagimet Biosciences Inc. (SGMT) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.25 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +10.2% since its last earnings release on August 11, 2026.

Sagimet Biosciences Beat Consensus Estimates
Tuesday, August 11, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 7:30 AM ET
Earnings Whisper
-
vs ($0.25)
Rev est $69.37M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $9.90

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Sagimet Biosciences Inc.

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel therapeutics targeting dysfunctional metabolic pathways. Sagimet Biosciences Inc. is based in SAN MATEO, Calif.

Sector

Healthcare

Industry

Biotechnology